{"entity":{"id":"ast-202","kind":"drug","name":"AST-202","aka":[],"tldr":"AST-202 is an experimental aptamer-drug conjugate from Aptamer Sciences, in preclinical development for blood cancers and solid tumours.","summary":"AST-202 is an aptamer-drug conjugate (ApDC) from Aptamer Sciences. A CD25-binding aptamer joined to a cytotoxic drug, designed to deplete regulatory T cells in tumours and to act directly on blood cancers that overexpress CD25. Its furthest stage is preclinical development, for blood cancers and solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Aptamer Sciences: aptsci.com","url":"https://www.aptsci.com/en/pipeline/pipeline.php"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["cd25"],"drugs":[],"companies":["aptamer-sciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AST-202","modality":"Aptamer-drug conjugate (ApDC)","mechanism":"A CD25-binding aptamer joined to a cytotoxic drug, designed to deplete regulatory T cells in tumours and to act directly on blood cancers that overexpress CD25.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ast-202/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"cd25","kind":"target","name":"CD25 (IL-2 receptor alpha)","route":"/targets/cd25/"}],"company":[{"id":"aptamer-sciences","kind":"company","name":"Aptamer Sciences","route":"/companies/aptamer-sciences/"}]}}